Vivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera optionnews2026-04-10T15:13:51+00:00April 10th, 2026|Endpoints News|
FDA lifts MacroGenics hold; Oxford and Bristol Myers team upnews2026-04-09T15:10:37+00:00April 9th, 2026|Endpoints News|
Merck adjusts its vaccine supply deal in China; Soleno withdraws EU applicationnews2026-04-08T15:24:21+00:00April 8th, 2026|Endpoints News|
Novo launches high-dose Wegovy in the US; Evotec pressured to list its US unitnews2026-04-07T15:14:50+00:00April 7th, 2026|Endpoints News|
Anthropic pays $400M for biotech; Praxis epilepsy drug hits in Phase 1/2 trialnews2026-04-06T14:37:53+00:00April 6th, 2026|Endpoints News|
Lipocine’s postpartum depression drug fails; AstraZeneca claims liver cancer winnews2026-04-02T14:42:52+00:00April 2nd, 2026|Endpoints News|
Amgen, Zai Lab team up on DLL3; Janux gets $35M milestone paymentnews2026-04-01T15:26:47+00:00April 1st, 2026|Endpoints News|
Takeda cuts 600+ US jobs; United’s stock rises on Tyvaso datanews2026-03-30T15:01:45+00:00March 30th, 2026|Endpoints News|
AnaptysBio spins out biotech operations; Affibody’s data in hidradenitis suppurativanews2026-03-27T15:33:54+00:00March 27th, 2026|Endpoints News|
Kodiak’s Phase 3 eye drug success; Innate discontinues anti-CD20 programnews2026-03-26T14:28:58+00:00March 26th, 2026|Endpoints News|
